Multicenter study suggests early rasburicase prevents kidney failure and death in tumor lysis syndrome

Article Title

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial

COI Statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: AMA received research support from the American Heart Association and National Institutes of Health and consulting fees from HealthCentral. ASLC served as a consultant for Kite Pharma, Genmab, Pierre Fabre, and Takeda. CB received research support from Fresenius Medical Care. DEL received research support from BTG International, Metro International Biotech, Renibus Therapeutics, Alexion Pharmaceuticals, and 60 Degrees Pharmaceuticals and served as a consultant for Entrada Therapeutics, CardioRenal Systems, and Alexion Pharmaceuticals and as a co-chair of a safety monitoring committee for EMD Serono Research and Development Institute. MES received research funding from Otsuka, Gilead, Cabaletta, Novartis, Roche/Genetech, Merck, Amgen, and Astrazeneca, served on scientific advisory boards or had scientific consulting agreements with Vera, Travere, Novartis, Otsuka, Relay TX, Merida Biosciences, Medibeacon, and Vera, and is a data safety monitoring committee member for Alpine Immune Sciences/Vertex. MGSS received research support from Senticell. PA received research funding from Merck, BMS-Celgene, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM, Astra Zeneca, Lilly Loxo, and Kite, served as a consultant for Merck, BMS/Celgene, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, Genentech/Roche, Xencor, Foresight, ATB Therapeutics, and Lilly Loxo, and received honorariums from Merck and BMS. RB received research support to institution from AbbVie, Regeneron, Janssen, Karyopharm, and BMS and was advisory board member for Janssen, Pfizer, and Sanofi. RP served as a consultant for Sanofi and Merck Research and received travel honorariums from Octapharma. SA served as site investigator for the VOICE study, sponsored by US Renal Care and Akebia therapeutics. SG received research support from BTG International, AstraZeneca, and Janssen and served as a consultant for Mersana Therapeutics, MediBeacon, Alexion, BTG International, and Orion Pharma. All other authors declare no disclosures.